{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:02:21Z","timestamp":1779332541120,"version":"3.51.4"},"reference-count":28,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"K.G. Jebsen Center for Cardiac Research","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,5,20]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To quantify longitudinal development of disease activity, organ damage, patient-reported outcomes, and myositis autoantibody profiles in patients with juvenile dermatomyositis (JDM) after long-term follow-up, and to identify predictors for persistent active disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Forty patients (65% female) diagnosed with JDM were clinically examined at two different time points (visits 1 and 2). We assessed clinically inactive\/active disease by the updated PRINTO criteria and the Juvenile DermatoMyositis Activity Index (JDMAI). Organ damage was evaluated by Myositis Damage Index (MDI) and physical function by Childhood Health Assessment Questionnaire (CHAQ\/HAQ). Myositis autoantibodies were measured by myositis line immunoassay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median disease duration from symptom onset was 15.1 (2.0\u201334.6) at visit 1 and 21.7 (7.6\u201342.7) years at visit 2. At visit 2, active disease (PRINTO) was found in 53%, impaired physical function (CHAQ\/HAQ&gt;0) in 40%, organ damage (MDI<jats:sub>total<\/jats:sub>\u22651) in 95% and myositis specific or associated antibodies in 33% of patients. Disease activity (JDMAI) was low in 24%, moderate in 8% and high in 3% of patients. There were no significant differences in organ damage and disease activity between visits. Higher disease activity and organ damage at visit 1 predicted persistent active disease at visit 2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>After a median of 21.7 years from symptom onset, the majority of JDM patients still had active disease. Higher organ damage and disease activity at the initial visit predicted persistent active disease at follow-up. These results underscore the chronic nature of JDM, emphasising the need for enhanced early and long-term management strategies to improve patient outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005598","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:05:16Z","timestamp":1749182716000},"page":"e005598","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Predictors of persistent active disease and the longitudinal development of organ damage, patient-reported outcomes and autoantibodies in long-term juvenile dermatomyositis"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4744-3637","authenticated-orcid":false,"given":"Simon Girmai","family":"Berger","sequence":"first","affiliation":[{"name":"Oslo University Hospital Institute for Experimental Medical Research, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin Schjander","family":"Berntsen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital Division of Surgery and Specialized Medicine, Oslo, Oslo, Norway"},{"name":"Martina Hansens Hospital, Department of Rheumatology, Sandvika, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8210-0360","authenticated-orcid":false,"given":"Kristine","family":"Risum","sequence":"additional","affiliation":[{"name":"Oslo Metropolitan University, Oslo, Norway"},{"name":"Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henriette Schermacher","family":"Marstein","sequence":"additional","affiliation":[{"name":"Oslo University Hospital Institute for Experimental Medical Research, Oslo, Norway"},{"name":"Department of Rheumatology, Oslo University Hospital Division of Surgery and Specialized Medicine, Oslo, Oslo, Norway"},{"name":"Oslo New University College, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivar","family":"Sjaastad","sequence":"additional","affiliation":[{"name":"Oslo University Hospital Institute for Experimental Medical Research, Oslo, Norway"},{"name":"Department of Cardiology, Oslo University Hospital Ullev\u00e5l, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathis Korseberg","family":"Stokke","sequence":"additional","affiliation":[{"name":"Oslo University Hospital Institute for Experimental Medical Research, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7226-066X","authenticated-orcid":false,"given":"Helga","family":"Sanner","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital Division of Surgery and Specialized Medicine, Oslo, Oslo, Norway"},{"name":"Oslo New University College, Oslo, Norway"},{"name":"Institute for Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2025090313264699000_11.2.e005598.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60955-1"},{"key":"2025090313264699000_11.2.e005598.2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/acr.20015","article-title":"Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients","volume":"62","author":"Ravelli","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313264699000_11.2.e005598.3","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2011.608376"},{"key":"2025090313264699000_11.2.e005598.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep302"},{"key":"2025090313264699000_11.2.e005598.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu146"},{"key":"2025090313264699000_11.2.e005598.6","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003093","article-title":"Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index","volume":"10","author":"Rosina","year":"2024","journal-title":"RMD Open"},{"key":"2025090313264699000_11.2.e005598.7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/rheumatology\/key421","article-title":"Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis","volume":"58","author":"Rosina","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313264699000_11.2.e005598.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468"},{"key":"2025090313264699000_11.2.e005598.9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J Intern Med"},{"key":"2025090313264699000_11.2.e005598.10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/rheumatology\/key342","article-title":"Cardiorespiratory fitness in long-term juvenile dermatomyositis: a controlled, cross-sectional study of active\/inactive disease","volume":"58","author":"Berntsen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313264699000_11.2.e005598.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.10924"},{"key":"2025090313264699000_11.2.e005598.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg427"},{"key":"2025090313264699000_11.2.e005598.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.23963"},{"key":"2025090313264699000_11.2.e005598.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.11.1262"},{"key":"2025090313264699000_11.2.e005598.15","first-page":"118","article-title":"Measures of Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS)","volume":"11","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2025090313264699000_11.2.e005598.16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20035","article-title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies","volume":"62","author":"Rider","year":"2010","journal-title":"Arthritis Care & Research"},{"key":"2025090313264699000_11.2.e005598.17","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8"},{"key":"2025090313264699000_11.2.e005598.18","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/acr.23491","article-title":"Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care","volume":"70","author":"Varnier","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313264699000_11.2.e005598.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"2025090313264699000_11.2.e005598.20","first-page":"326","article-title":"Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire","volume":"22","author":"Feldman","year":"1995","journal-title":"J Rheumatol"},{"key":"2025090313264699000_11.2.e005598.21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/14034948980260040401","article-title":"Short form 36 (SF-36) health survey: normative data from the general Norwegian population","volume":"26","author":"Loge","year":"1998","journal-title":"Scand J Soc Med"},{"key":"2025090313264699000_11.2.e005598.22","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.39200","article-title":"Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated","volume":"67","author":"Almeida","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090313264699000_11.2.e005598.23","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/annrheumdis-2017-211401","article-title":"American College of Rheumatology\/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Rider","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090313264699000_11.2.e005598.24","unstructured":"Web calculator for 2016 ACR\/EULAR criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis, 2016. Available: www.niehs.nih.gov\/research\/resources\/imacs\/response_criteria\/pediatric.html"},{"key":"2025090313264699000_11.2.e005598.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.24904"},{"key":"2025090313264699000_11.2.e005598.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa497"},{"key":"2025090313264699000_11.2.e005598.27","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1093\/rheumatology\/keac682","article-title":"Cumulative disease damage and anti-PM\/Scl antibodies are associated with a heavy burden of calcinosis in systemic sclerosis","volume":"62","author":"Richardson","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313264699000_11.2.e005598.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.20179"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:26:55Z","timestamp":1756931215000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,5]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/rmdopen-2025-005598"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005598","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}